vs
Medpace Holdings, Inc.（MEDP）与Martin Marietta Materials（MLM）财务数据对比。点击上方公司名可切换其他公司
Martin Marietta Materials的季度营收约是Medpace Holdings, Inc.的1.9倍（$1.4B vs $708.5M），Martin Marietta Materials净利率更高（111.1% vs 19.1%，领先92.0%），Medpace Holdings, Inc.同比增速更快（32.0% vs 17.0%），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -12.1%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
马丁·玛丽埃塔材料公司是美国大型集料及重型建筑材料供应商，业务覆盖美国26个州、加拿大及加勒比地区，主要为道路、人行道、地基等各类基建项目提供所需原材料。
MEDP vs MLM — 直观对比
营收规模更大
MLM
是对方的1.9倍
$708.5M
营收增速更快
MEDP
高出15.0%
17.0%
净利率更高
MLM
高出92.0%
19.1%
两年增速更快
MEDP
近两年复合增速
-12.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $1.4B |
| 净利润 | $135.1M | $1.5B |
| 毛利率 | — | 22.8% |
| 营业利润率 | 21.6% | 11.9% |
| 净利率 | 19.1% | 111.1% |
| 营收同比 | 32.0% | 17.0% |
| 净利润同比 | 15.5% | — |
| 每股收益（稀释后） | $4.65 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPMLM
| Q1 26 | — | $1.4B | ||
| Q4 25 | $708.5M | $1.1B | ||
| Q3 25 | $659.9M | $1.8B | ||
| Q2 25 | $603.3M | $1.8B | ||
| Q1 25 | $558.6M | $1.4B | ||
| Q4 24 | $536.6M | $1.6B | ||
| Q3 24 | $533.3M | $1.9B | ||
| Q2 24 | $528.1M | $1.8B |
净利润MEDPMLM
| Q1 26 | — | $1.5B | ||
| Q4 25 | $135.1M | $279.0M | ||
| Q3 25 | $111.1M | $414.0M | ||
| Q2 25 | $90.3M | $328.0M | ||
| Q1 25 | $114.6M | $116.0M | ||
| Q4 24 | $117.0M | $293.0M | ||
| Q3 24 | $96.4M | $363.0M | ||
| Q2 24 | $88.4M | $294.0M |
毛利率MEDPMLM
| Q1 26 | — | 22.8% | ||
| Q4 25 | — | 35.0% | ||
| Q3 25 | — | 33.1% | ||
| Q2 25 | — | 30.0% | ||
| Q1 25 | — | 24.8% | ||
| Q4 24 | — | 30.0% | ||
| Q3 24 | — | 31.7% | ||
| Q2 24 | — | 29.3% |
营业利润率MEDPMLM
| Q1 26 | — | 11.9% | ||
| Q4 25 | 21.6% | 24.6% | ||
| Q3 25 | 21.5% | 27.4% | ||
| Q2 25 | 20.9% | 25.3% | ||
| Q1 25 | 20.3% | 14.3% | ||
| Q4 24 | 23.4% | 24.4% | ||
| Q3 24 | 21.1% | 25.9% | ||
| Q2 24 | 19.9% | 22.6% |
净利率MEDPMLM
| Q1 26 | — | 111.1% | ||
| Q4 25 | 19.1% | 24.5% | ||
| Q3 25 | 16.8% | 22.4% | ||
| Q2 25 | 15.0% | 18.1% | ||
| Q1 25 | 20.5% | 8.6% | ||
| Q4 24 | 21.8% | 18.0% | ||
| Q3 24 | 18.1% | 19.2% | ||
| Q2 24 | 16.7% | 16.7% |
每股收益（稀释后）MEDPMLM
| Q1 26 | — | — | ||
| Q4 25 | $4.65 | $4.59 | ||
| Q3 25 | $3.86 | $6.85 | ||
| Q2 25 | $3.10 | $5.43 | ||
| Q1 25 | $3.67 | $1.90 | ||
| Q4 24 | $3.67 | $4.87 | ||
| Q3 24 | $3.01 | $5.91 | ||
| Q2 24 | $2.75 | $4.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $273.0M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $459.1M | $11.3B |
| 总资产 | $2.0B | $20.5B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资MEDPMLM
| Q1 26 | — | $273.0M | ||
| Q4 25 | $497.0M | $67.0M | ||
| Q3 25 | $285.4M | $57.0M | ||
| Q2 25 | $46.3M | $225.0M | ||
| Q1 25 | $441.4M | $101.0M | ||
| Q4 24 | $669.4M | $670.0M | ||
| Q3 24 | $656.9M | $52.0M | ||
| Q2 24 | $510.9M | $109.0M |
总债务MEDPMLM
| Q1 26 | — | $0 | ||
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.5B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | — | $4.3B |
股东权益MEDPMLM
| Q1 26 | — | $11.3B | ||
| Q4 25 | $459.1M | $10.0B | ||
| Q3 25 | $293.6M | $9.7B | ||
| Q2 25 | $172.4M | $9.4B | ||
| Q1 25 | $593.6M | $9.1B | ||
| Q4 24 | $825.5M | $9.5B | ||
| Q3 24 | $881.4M | $9.2B | ||
| Q2 24 | $763.6M | $8.8B |
总资产MEDPMLM
| Q1 26 | — | $20.5B | ||
| Q4 25 | $2.0B | $18.7B | ||
| Q3 25 | $1.8B | $18.7B | ||
| Q2 25 | $1.6B | $18.1B | ||
| Q1 25 | $1.9B | $17.7B | ||
| Q4 24 | $2.1B | $18.2B | ||
| Q3 24 | $2.1B | $16.5B | ||
| Q2 24 | $1.9B | $16.3B |
负债/权益比MEDPMLM
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.53× | ||
| Q3 25 | — | 0.57× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.57× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $227.0M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 0.6% | 40.4% |
| 现金转化率经营现金流/净利润 | 1.43× | 0.15× |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPMLM
| Q1 26 | — | $227.0M | ||
| Q4 25 | $192.7M | $629.0M | ||
| Q3 25 | $246.2M | $551.0M | ||
| Q2 25 | $148.5M | $387.0M | ||
| Q1 25 | $125.8M | $218.0M | ||
| Q4 24 | $190.7M | $686.0M | ||
| Q3 24 | $149.1M | $600.0M | ||
| Q2 24 | $116.4M | $1.0M |
自由现金流MEDPMLM
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $424.0M | ||
| Q3 25 | $235.5M | $361.0M | ||
| Q2 25 | $142.4M | $208.0M | ||
| Q1 25 | $115.8M | $-15.0M | ||
| Q4 24 | $183.0M | $453.0M | ||
| Q3 24 | $138.5M | $317.0M | ||
| Q2 24 | $103.5M | $-138.0M |
自由现金流率MEDPMLM
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 37.2% | ||
| Q3 25 | 35.7% | 19.6% | ||
| Q2 25 | 23.6% | 11.5% | ||
| Q1 25 | 20.7% | -1.1% | ||
| Q4 24 | 34.1% | 27.8% | ||
| Q3 24 | 26.0% | 16.8% | ||
| Q2 24 | 19.6% | -7.8% |
资本支出强度MEDPMLM
| Q1 26 | — | 40.4% | ||
| Q4 25 | 0.6% | 18.0% | ||
| Q3 25 | 1.6% | 10.3% | ||
| Q2 25 | 1.0% | 9.9% | ||
| Q1 25 | 1.8% | 17.2% | ||
| Q4 24 | 1.4% | 14.3% | ||
| Q3 24 | 2.0% | 15.0% | ||
| Q2 24 | 2.4% | 7.9% |
现金转化率MEDPMLM
| Q1 26 | — | 0.15× | ||
| Q4 25 | 1.43× | 2.25× | ||
| Q3 25 | 2.22× | 1.33× | ||
| Q2 25 | 1.65× | 1.18× | ||
| Q1 25 | 1.10× | 1.88× | ||
| Q4 24 | 1.63× | 2.34× | ||
| Q3 24 | 1.55× | 1.65× | ||
| Q2 24 | 1.32× | 0.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
MLM
暂无分部数据
